New York, USA – September 27, 2023 – Amidst the relentless SARS-CoV-2 pandemic, Creative Biolabs proactively embraced the challenge, amassing extensive expertise in delivering comprehensive services for vaccine and antiviral drug discovery to global scientists.
“At the close of 2019, when the world first encountered the SARS-CoV-2 virus, the rapidity of its spread and the severity of symptoms left people astounded,” remarked the Chief Expert at Creative Biolabs. “To curb the virus’s spread and avert infections, Creative Biolabs swiftly plunged into the realm of antiviral vaccine discovery.”
After years of aiding vaccine researchers worldwide, Creative Biolabs has now mastered cutting-edge technologies and established an all-encompassing system for SARS-CoV-2 vaccine discovery and design. This system spans from initial target identification to immune response analysis, antigen development, subsequent attenuation testing, antibody and antigen detection, and stability assessments.
Moreover, Creative Biolabs supports the development of various vaccine types for preclinical and clinical phases, including but not limited to:
* In Silico Vaccine Design
* SARS-CoV-2 DNA Vaccine
* Formulation Optimization Platform for SARS-CoV-2 Vaccine
* Virus-Like-Particles Based SARS-CoV-2 Vaccine Development
The expert further elaborated, saying, “Creative Biolabs customizes its services to align with clients’ experimental requirements. For instance, we have successfully developed SARS-CoV-2 virus-like particles and offer VLP expression systems, including mammalian cells (293T, CHO), yeast, recombinant vaccinia virus, and baculovirus expression systems, allowing vaccine researchers to select the best fit.”
With the SARS-CoV-2 virus’s widespread transmission and its ongoing presence in countries across the globe, Creative Biolabs has long been collaborating with researchers in the field of antiviral drug discovery to expedite efforts against SARS-CoV-2.
“Creative Biolabs boasts an adept team proficient in drug screening and development, committed to advancing researchers’ drug discovery endeavors. One strategy provided by Creative Biolabs involves employing multiple reverse genetics systems targeting SARS-CoV-2 to delve into the virus’s lifecycle, replication, transcription, and pathophysiology.”
Reverse genetics systems have emerged as a potent tool in the quest for therapeutics against viral infections and have gained considerable traction in SARS-CoV-2 drug discovery research. Furthermore, Creative Biolabs employs high-throughput screening methods to identify and assess potential drugs capable of disrupting SARS-CoV-2 RNA synthesis, thus hindering the virus’s replication, such as RNA synthesis inhibitors for SARS-CoV-2.
“RNA synthesis inhibitors disrupt the RNA replication process in the SARS-CoV-2 virus, impeding its lifecycle and consequently slowing down or preventing its replication and spread within host cells,” elucidated the expert. “Within Creative Biolabs’ extensive drug discovery platform, analogous solutions encompass protease inhibitors, Abelson kinase inhibitors, nucleoside analogue inhibitors, and more.”
In addition to evaluating their inhibitory effects on SARS-CoV-2, Creative Biolabs also conducts biological activity testing of antiviral compounds to pinpoint the most promising drug candidates.
For comprehensive insights into Creative Biolabs’ services geared towards combating the SARS-CoV-2 virus, please visit https://sars-cov-2.creative-biolabs.com.
About
In the latter half of 2023, Creative Biolabs embarked on a journey of participation, showcasing its expertise and technologies at summits and exhibitions across various life science domains. Engaging in discussions with scientists worldwide, Creative Biolabs explored the future possibilities of global health.
Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-830-6441Country: United StatesWebsite: https://sars-cov-2.creative-biolabs.com
